Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

Table 1 sCD73 activity in metastatic melanoma patients

	n	SCD73 activity pmol/min/mg protein [median (range)]	P value^a
Gender
Male	21	26.7 (0.0–255.3)	0.007
Female	16	0.0 (0.0–75.8)	0.007
Age (years)
< 62	18	21.9 (0.0–93.7)	0.16
≥ 62	19	6.4 (0.0–255.3)	0.16
BRAF status
Wt	19	16.5 (0.0–90.9)	0.99
Mutated	13	13.9 (0.0–255.3)	0.99
Brain mets
Yes	7	16.0 (0.0–90.9)	0.84
No	27	13.9 (0.0–255.3)	0.84
LDH (IU/L)
< 480	17	7.2 (0.0–90.9)	0.11
> 480	19	25.2 (0.0–255.3)	0.11
N of previous therapy line
2	24	10.0 (0.0–93.7)	0.28
> 2	12	19.5 (0.0–255.3)	0.28

WT wild-type, mets: metastasis, LDH lactate dehydrogenase, IU/L International Units per Liter, N number
^aMann–Whitney U test

ISSN: 1479-5876